Scoop: Sanofi quietly ties up with a low-profile, preclinical cancer biotech — FTC signs off
Sanofi CEO Paul Hudson is building up the oncology cupboard.
The FTC noted on Tuesday that it has approved a deal between Sanofi — listed as the “acquiring party” — and Nurix Therapeutics, the “acquired party.” The tie-up has never been mentioned publicly.
A spokesperson for Sanofi tells me via e-mail that the two companies have a research collaboration they plan to spotlight next week at JP Morgan, with Nurix execs expected to offer more details in the days to come. A representative of the biotech confirmed that they would be outlining the alliance next week.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.